Invitae Corporation

Equities

NVTA.Q

US46185L1035

Biotechnology & Medical Research

End-of-day quote OTC Markets Other stock markets 18:00:00 2024-05-16 EDT			5-day change	1st Jan Change
0.0005 ^USD	-75.00%		-16.67%	-99.92%

04-25	Labcorp beats quarterly estimates on strong testing demand	RE
04-25	Clinical lab operator Labcorp to buy bankrupt genetic test maker Invitae for $239 mln	RE

Invitae Corporation Reiterates Revenue Guidance for the Year 2022

August 09, 2022 at 04:05 pm

Invitae Corporation is reiterating its financial guidance. The company expects a low double-digit growth rate for its full year 2022 revenue over 2021. Longer term revenue growth rate is expected to return to between 15% and 25% beyond 2023.

Latest news about Invitae Corporation

Labcorp beats quarterly estimates on strong testing demand	04-25	RE
Clinical lab operator Labcorp to buy bankrupt genetic test maker Invitae for $239 mln	04-24	RE
Laboratory Corporation of America Holdings (NYSE:LH) won the bid to acquire substantially all of the assets of Invitae Corporation for approximately $240 million.	04-23	CI
Laboratory Corporation of America Holdings (NYSE:LH) agreed to acquire Substantially all Assets of Invitae Corporation (OTCPK:NVTA.Q).	04-23	CI
Invitae Unveils New Research for Breast Cancer Patients with Variants of Uncertain Significance	04-11	CI
Invitae Launches Update to Invitae Generation: Clinical Variant Modeling Improves Variant Classification	03-12	CI
Earnings Flash (NVTA) INVITAE CORPORATION Posts Q4 Revenue $127.8M	03-06	MT
Invitae Corporation Provides Unaudited Earnings Guidance for the Fourth Quarter and Full Year of 2023	03-06	CI
Bidding Procedure Approved for Invitae Corporation	02-15	CI
Motion for Joint Administration Approved for Invitae Corporation	02-15	CI
Invitae gets court approval for five-month bankruptcy sale	02-15	RE
Global markets live: Airbnb, Sony, Uber, Lyft, Nvidia...	02-14
Genetic test maker Invitae files for bankruptcy protection in US	02-13	RE
Motion for Asset Sale Filed by Invitae Corporation	02-13	CI
Invitae Corporation Lists Estimated Assets In The Range Of $500 Mln -$1 Bln - Court Filing	02-13	RE
INVITAE CORPORATION LISTS ESTIMATED LIABILITIES IN THE RANGE OF…	02-13	RE
Genetic test maker Invitae files for voluntary Chapter 11 protection	02-13	RE
Motion for Joint Administration Filed by Invitae Corporation	02-12	CI
Invitae Corporation Filed for Bankruptcy	02-12	CI
Invitae Corporation(OTCPK:NVTA) dropped from S&P Global BMI Index	02-08	CI
Invitae Corporation(OTCPK:NVTA) dropped from S&P TMI Index	02-08	CI
Global markets live: BP, Palantir, Infineon, Toyota, UBS...	02-06
Invitae Corporation May File for Bankruptcy	02-06	CI
Sector Update: Health Care Stocks Rise Late Afternoon	02-05	MT
Sector Update: Health Care Stocks Advance Monday Afternoon	02-05	MT

Chart Invitae Corporation

Duration

Period

More charts

Company Profile

Invitae Corporation is a medical genetics company. The Company is engaged in delivering genetic testing services, digital health solutions, and health data services that support a lifetime of patient care and improved outcomes. It offers genetic testing across multiple clinical areas, including hereditary cancer, precision oncology, women's health, rare diseases and pharmacogenomics. It applies proprietary design, process automation, robotics and bioinformatics software solutions to expand the use and impact of genetic information in sample processing and complex variant interpretation, allowing medical interpretation at scale. The Company also utilizes digital health solutions to improve ease-of-use and to deliver actionable information about risk, prevention, treatment, and monitoring. The Company has served over 3.6 million patients, and over 2.2 million of those patients have made their information available for data sharing.

Sector

Biotechnology & Medical Research

Calendar

2024-08-05 - Q2 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

	1st Jan change	Capi.
INVITAE CORPORATION	-99.92%	143K
EXACT SCIENCES CORPORATION	-31.90%	9.3B
GUARDANT HEALTH, INC.	-6.25%	3.1B
BGI GENOMICS CO., LTD.	-13.96%	2.17B
VERACYTE, INC.	-16.83%	1.75B
MARAVAI LIFESCIENCES HOLDINGS, INC.	+72.82%	1.5B
CAREDX, INC	+29.17%	807M
SEEGENE, INC.	-2.62%	759M
ADAPTIVE BIOTECHNOLOGIES CORPORATION	-26.33%	532M
CURIOX BIOSYSTEMS CO., LTD	+4.97%	313M

Bio Diagnostics & Testing